A Randomised, Double-Blind, 2-Period Crossover Study to Assess the Effect of Steady-State AZD6140 on the Pharmacokinetics of a Single Oral 500-mg Dose of Tolbutamide, a Substrate of CYP2C9, in Healthy Male and Female Volunteers.

Study identifier:D5130C00051

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomised, Double-Blind, 2-Period Crossover Study to Assess the Effect of Steady-State AZD6140 on the Pharmacokinetics of a Single Oral 500-mg Dose of Tolbutamide, a Substrate of CYP2C9, in Healthy Male and Female Volunteers.

Medical condition

Acute Coronary Syndrome

Phase

Phase 1

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Interventional

Age

Date

Study Start Date: 01 Jan 2007

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2453&filename=CSP-D5130C00051.pdf
Download
CSP-D5130C00051.pdf
Download
Trial Results Summaries
Available here

A Randomised, Double-Blind, 2-Period Crossover Study to Assess the Effect of Steady-State AZD6140 on the Pharmacokinetics of a Single Oral 500-mg Dose of Tolbutamide, a Substrate of CYP2C9, in Healthy Male and Female Volunteers.

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2453&filename=CSP-D5130C00051.pdf

CSP-D5130C00051.pdf

Trial Results Summaries